{"cluster": 62, "subcluster": 14, "abstract_summ": "In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (Mpro).Our study demonstrates that the fragment-based approach is a feasible strategy for identifying low\u2013molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs.As low\u2013molecular-weight drugs have high potential to completely match interactions with essential SARS-CoV-2 targets, we propose a strategy to identify such drugs using the fragment-based approach.Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of Mpro.The approved drugs for similar health problems, reported potential drugs but not yet approved clinically or under clinical trial, and molecules from medicinal plants extracts are investigated randomly to deal with the COVID-19 infection.", "title_summ": "Repurposing low\u2013molecular-weight drugs against the main protease of severe acute respiratory syndrome coronavirus 2Searching inhibitors for three important proteins of COVID-19 through molecular docking studiesStructure of Mpro from COVID-19 virus and discovery of its inhibitors.", "title_abstract_phrases": "In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (Mpro).Our study demonstrates that the fragment-based approach is a feasible strategy for identifying low\u2013molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs.As low\u2013molecular-weight drugs have high potential to completely match interactions with essential SARS-CoV-2 targets, we propose a strategy to identify such drugs using the fragment-based approach.Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of Mpro.The approved drugs for similar health problems, reported potential drugs but not yet approved clinically or under clinical trial, and molecules from medicinal plants extracts are investigated randomly to deal with the COVID-19 infection."}